Compare IVA & NOAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IVA | NOAH |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | France | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 796.1M | 653.4M |
| IPO Year | 2020 | 2010 |
| Metric | IVA | NOAH |
|---|---|---|
| Price | $3.12 | $7.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $15.20 | $10.62 |
| AVG Volume (30 Days) | ★ 2.3M | 89.6K |
| Earning Date | 09-28-2026 | 11-24-2026 |
| Dividend Yield | N/A | ★ 9.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.29 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.11 | $7.55 |
| 52 Week High | $7.98 | $12.45 |
| Indicator | IVA | NOAH |
|---|---|---|
| Relative Strength Index (RSI) | 32.53 | 27.60 |
| Support Level | N/A | N/A |
| Resistance Level | $4.80 | $8.17 |
| Average True Range (ATR) | 0.25 | 0.17 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 3.08 | 8.57 |
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.